Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493615 | 0.77 | — | — | |
| SCHEMBL6665129 | 0.71 | MEN1 (0.36) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL577610 | 0.71 | MEN1 (0.36) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL15981258 | 0.70 | MEN1 (0.35) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL2512554 | 0.68 | MEN1 (0.34) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL9499516 | 0.68 | HPGD (0.37) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL31001736 | 0.67 | ALDH1A1 (0.48) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL255970 | 0.67 | ALDH1A1 (0.48) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL519190 | 0.67 | MEN1 (0.46) | MEN1ALDH1A1GAAKMT2ARYR2 | |
| SCHEMBL15981254 | 0.66 | MEN1 (0.33) | MEN1ALDH1A1GAAKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087798-A1 | Novel amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | US | disclosed |
| EP-1264820-A1 | NOVEL AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087798-A1 | Novel amide compounds | H1-2, H1-0, H1-3 | MEN1 970/4885ALDH1A1 1144/4885GAA 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.